ReShape loans $200K to Vyome at 8% to fund merger-related expenses

Vyome Holdings, Inc

ReShape (RSLS) issued a $200,000 promissory note to Vyome Therapeutics, bearing 8.0% interest per annum.
Proceeds used for working capital and legal/accounting expenses related to the pending merger under July 8, 2024 agreement.
Note matures on September 30, 2025; if merger closes before then, principal and interest become ReShape net cash.
If merger fails due to Concurrent Financing Default, note becomes senior secured debt of Vyome.
Termination fee reduced by outstanding principal and interest under this note and a prior April 15, 2025 note.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.